Literature DB >> 7097496

High-performance liquid chromatographic assay for bumetanide in plasma and urine.

D E Smith.   

Abstract

A new high-performance liquid chromatographic (HPLC) method was developed for the analysis of bumetanide in plasma and urine. A reversed-phase column was fitted to the instrument and fluorescent (excitation lambda = 338 nm, emission lambda = 433 nm) and UV (254 nm) detectors were utilized to monitor simultaneously bumetanide and the internal standard, acetophenone, respectively. The assay is rapid, sensitive, and specific. Plasma bumetanide concentrations can be detected as low as 5 ng/ml using a 0.20-ml sample. Time-consuming extraction and/or derivatization steps are not required. The only clean-up procedure involved is the precipitation of plasma proteins with acetonitrile.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7097496     DOI: 10.1002/jps.2600710510

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  Sensitive isotope dilution liquid chromatography/tandem mass spectrometry method for quantitative analysis of bumetanide in serum and brain tissue.

Authors:  Yijun Li; Ryan Cleary; Mark Kellogg; Janet S Soul; Gerard T Berry; Frances E Jensen
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-02-19       Impact factor: 3.205

2.  Development of acute tolerance to bumetanide: constant-rate infusion studies.

Authors:  J A Cook; D E Smith
Journal:  Pharm Res       Date:  1988-02       Impact factor: 4.200

3.  Determinants of bumetanide response in the dog: effect of probenecid.

Authors:  D E Smith; H S Lau
Journal:  J Pharmacokinet Biopharm       Date:  1983-02

4.  Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments.

Authors:  S H Lee; M G Lee; N D Kim
Journal:  J Pharmacokinet Biopharm       Date:  1994-02

5.  Development of acute tolerance to bumetanide: bolus injection studies.

Authors:  J A Cook; D E Smith
Journal:  Pharm Res       Date:  1987-10       Impact factor: 4.200

6.  Metabolism of the diuretic bumetanide in healthy subjects and patients with renal impairment.

Authors:  M R Howlett; G G Skellern; W H Auld; W R Murdoch
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 7.  Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.

Authors:  A Ward; R C Heel
Journal:  Drugs       Date:  1984-11       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.